Investment Rating - The report maintains a "Buy" investment rating for the company [2][3]. Core Insights - The company achieved a revenue of 1.017 billion yuan in 2023, representing a year-on-year increase of 67.51%, and a net profit attributable to shareholders of 272 million yuan, up 40.07% from the previous year [2]. - In Q1 2024, the company reported a revenue of 216 million yuan, a 34.04% increase year-on-year, with a net profit of 50 million yuan, reflecting a 42.06% growth [2]. - The company has a robust order backlog, with new orders amounting to 1.36 billion yuan in 2023, a 35.06% increase year-on-year, and a total order amount of 1.586 billion yuan, up 18.90% [2]. - The company’s contract research and development services, along with technology transfer and revenue-sharing businesses, generated 953 million yuan in revenue, marking a 65.16% increase, with a gross margin of 67.36% [2]. - The company has a rich pipeline of nearly 300 self-developed projects awaiting transformation, with 85 projects currently under revenue-sharing agreements [2]. Summary by Sections Financial Performance - The company forecasts revenues of 1.364 billion yuan for 2024, 1.819 billion yuan for 2025, and 2.373 billion yuan for 2026, with corresponding net profits of 361 million yuan, 478 million yuan, and 619 million yuan respectively [3]. - The earnings per share (EPS) are projected to be 3.32 yuan in 2024, 4.39 yuan in 2025, and 5.68 yuan in 2026, with price-to-earnings (P/E) ratios of 20.8, 15.7, and 12.1 respectively [3]. Business Development - The company is enhancing its integrated service system to support the growth of its CDMO (Contract Development and Manufacturing Organization) business, with a production facility covering 136,000 square meters and capable of producing 24 dosage forms [2]. - The company has successfully completed 360 projects in 2023, with external customer orders generating 52.49 million yuan in revenue, a significant increase of 152.35% [2].
公司事件点评报告：业绩符合预期，在手订单稳健增长